



Sheet 1 of 8

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Minotti et al.	CONFIRMATION NO.
(Use several sheets if necessary)		FILING DATE December 4, 2003	GROUP 1623

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
M		4,203,900	05/20/90	Kaiser	—	—	
		4,206,221	06/03/90	Miller et al.	—	—	
		4,303,439	12/01/81	Howe et al.	—	—	
		4,354,029	10/12/82	Kaiser et al.	—	—	
		4,360,678	11/23/82	Howe et al.	—	—	
		4,443,611	04/17/84	Kaiser	—	—	
		4,543,414	09/24/85	Carson	—	—	
		4,743,700	05/10/88	Jamm et al.	—	—	
		4,814,470	03/21/89	Colin et al.	—	—	
		4,857,653	08/15/89	Colin et al.	—	—	
		4,876,399	10/24/89	Holton et al.	—	—	
		4,877,881	10/31/89	Belliotti et al.	—	—	
		4,924,002	05/08/90	Kostlan	—	—	
		4,924,011	05/08/90	Denis et al.	—	—	
		4,924,012	05/08/90	Colin et al.	—	—	
M		4,942,184	07/17/90	Haugwitz et al.	—	—	

EXAMINER M. Howe DATE CONSIDERED 9/16/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Minotti et al.

CONFIRMATION NO.

FILING DATE
December 4, 2003

GROUP
1623

	4,960,790	10/02/90	Stella et al.	—	—	
	5,015,744	05/14/91	Hotan	—	—	
	5,059,699	10/22/91	Kingston et al.	—	—	
	5,128,478	07/07/92	Ito et al.	—	—	
	5,136,060	08/04/92	Holtan	—	—	
	5,194,635	03/16/93	Kingston et al.	—	—	
	5,208,237	05/04/93	Hewawasam et al.	—	—	
	5,227,400	07/13/93	Holton et al.	—	—	
	5,243,045	09/07/93	Holton et al.	—	—	
	5,254,580	10/19/93	Chen	—	—	
	5,264,591	11/23/93	Bombardelli et al.	—	—	
	5,272,171	12/21/93	Ueda et al.	—	—	
	5,278,324	01/11/94	Klingston et al.	—	—	
	5,283,253	02/01/94	Holton et al.	—	—	
	5,296,506	03/22/94	Kingston	—	—	
	5,319,112	06/07/94	Kingston et. al.	—	—	
	5,352,806	10/04/94	Gunawardana et al.	—	—	
M	5,399,726	03/21/95	Holton et al.	—	—	

EXAMINER

AV/Janet

DATE CONSIDERED

01/16/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Minotti et al.	CONFIRMATION NO.
		FILING DATE December 4, 2003	GROUP 1623

<i>AM</i>	5,420,337	05/30/95	Patel et al.	—	—	
	5,440,056	08/08/95	Klein et al.	—	—	
	5,449,790	09/12/95	Zheng et al.	—	—	
	5,468,769	11/21/95	Klein et al.	—	—	
	5,476,954	12/19/95	Borzat et al.	—	—	
	5,556,878	09/17/96	Kelly et al.	—	—	
	5,580,997	12/02/96	Bouchard et al.	—	—	
	5,589,502	12/31/96	Tsujihara et al.	—	—	
	5,616,739	04/01/97	Mas et al.	—	—	
	5,618,952	04/08/97	Holton et al.	—	—	
	5,621,121	04/15/97	Cammercon et al.	—	—	
	5,635,531	06/03/97	Chen	—	—	
	5,637,732	06/10/97	Holton et al.	—	—	
	5,646,176	07/08/97	Golik et al.	—	—	
	5,670,658	09/23/97	Bastart	—	—	
	5,677,470	10/14/97	Tsujihara et al.	—	—	
	5,710,287	01/20/98	Holton et al.	—	—	
<i>AM</i>	5,721,268	02/24/98	Holton et al.	—	—	

EXAMINER *AM* DATE CONSIDERED *1/16/04*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Minotti et al.

CONFIRMATION NO.

FILING DATE
December 4, 2003

GROUP
1623

<i>DM</i>	5,728,687	03/17/98	Bissery	—	—	
	5,728,725	03/17/98	Holton et al.	—	—	
	5,760,252	06/02/98	Holton et al.	—	—	
	5,767,296	06/16/98	Terasawa et al.	—	—	
	5,773,461	06/30/98	Wittma et al.	—	—	
	5,808,102	09/15/98	Poss et al.	—	—	
	5,840,931	11/24/98	Bouchard et al.	—	—	
	5,847,170	12/08/98	Bouchard et al.	—	—	
	5,889,043	03/30/99	Bouchard et al.	—	—	
	5,908,835	06/01/99	Bissery	—	—	
	6,005,120	12/21/99	Holton et al.	—	—	
	6,020,507	02/01/00	Gibson	—	—	
	6,043,375	03/28/00	Borzat et al.	—	—	
	6,072,060	06/06/00	Suidell et al.	—	—	
	6,096,909	08/01/00	Ojima	—	—	
	6,100,411	08/08/00	Ojima	—	—	
	6,214,863	04/10/01	Bissery	—	—	
<i>DM</i>	6,239,167	05/29/01	Bissery	—	—	


EXAMINER

dk/nan

DATE CONSIDERED

9/16/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
1188-37 RCE/DIVSERIAL NO.
10/728,015APPLICANT
Minotti et al.

CONFIRMATION NO.

FILING DATE
December 4, 2003GROUP
1623

<i>AM</i>		6,248,908	06/01	Kant	—	—	
		6,340,701	01/02	Chari et al.	—	—	
<i>AM</i>		6,353,120	03/02	Kant	—	—	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>AM</i>		JP 55-145650	11/13/80	Japan	—	—		
		JP 61-005022	01/10/86	Japan	—	—		
		JP 61-51578	11/10/86	Japan	—	—		
		JP 60-222416	11/07/85	Japan	—	—		
		JP 61-115022	06/02/86	Japan	—	—		
		JP 9208572A	08/12/97	Japan	—	—		
		WO 90/02738	03/22/90	PCT	—	—		
		WO 92/09589	06/11/92	PCT	—	—		
		WO 92/19765	11/12/92	PCT	—	—		
		WO 94/07876	04/14/94	PCT	—	—		
		WO 94/13655	06/23/94	PCT	—	—		
<i>AM</i>		WO 94/14787	07/07/94	PCT	—	—		

EXAMINER

AM

DATE CONSIDERED

9/16/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Minotti et al.	CONFIRMATION NO.
(Use several sheets if necessary)		FILING DATE December 4, 2003	GROUP 1623

<i>CHW</i>	WO 95/03265	02/02/95	PCT	—	—		
	WO 96/00724	01/11/96	PCT	—	—		
	WO 96/13495	05/09/96	PCT	—	—		
	WO 96/14309	05/17/96	PCT	—	—		
	WO 96/23779	08/08/96	PCT	—	—		
	WO 97/09979	03/20/97	PCT	—	—		
	WO 97/23472	07/03/97	PCT	—	—		
	WO 97/32578	09/12/97	PCT	—	—		
	WO 97/32869	09/12/97	PCT	—	—		
	WO 98/01435	01/15/98	PCT	—	—		
	WO 98/22451	05/28/98	PCT	—	—		
	WO 99/33462	07/08/99	PCT	—	—		
	EP 0 359 516 B1	08/10/94	EPO	—	—		
	EP 0 400 971 B1 & A3	07/29/98	EPO	—	—		
	EP 0 428 376 B1	01/10/96	EPO	—	—		
	EP 0 505 047 B1 & A1	04/24/96	EPO	—	—		
	EP 0 537 905 B1 & A1	03/06/96	EPO	—	—		
<i>M</i>	EP 0 604 910 A1	07/06/04	EPO	—	—		

EXAMINER *Michael* DATE CONSIDERED *1/16/04*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Minotti et al.	CONFIRMATION NO.
(Use several sheets if necessary)		FILING DATE December 4, 2003	GROUP 1623

M	1,061,330	08/28/79	Canada	-	-		
	1,695,918	05/06/71	German	-	-		
CM	2,919,891	12/04/80	German	-	-		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

all	Donnelli, M.G., et al; Pharmacokinetics of anticancer agents in patients with impaired liver function; European Journal of Cancer; Pergamon Press; Oxford, Great Britain; vol. 34, no. 1; January 1998
	ECCO: Taxol/doxorubicin Improves Survival in Metastatic Breast Cancer; Doctor's Guide, 'Online!', 22 September 1999; retrieved from the Internet: www.pslgroup.com/dg/13144a.htm; retrieved 2002-11-06.
	DG Dispatch - ECCO: New Drug Combination Enhances Treatment for Advanced Breast Cancer; Doctor's Guide; 'Online!'; 19 September 1999; retrieved from the Internet: www.pslgroup.com/dg/12c452.htm.
	Sparano, "Doxorubicin/Taxane combinations: Cardiac toxicity and pharmacokinetics." Seminars in Oncology, Vol. 26, No. 3, Suppl. 9 (June 1999), pages 14-19.
	Gianni et al., "Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel patients with breast cancer." Journal of clinical oncology, vol. 15, no. 5 (May 1997) pages 1906-1915.
all	Zoli et al. "In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers." Breast Cancer Research and Treatment, 34, 1995, pages 63-39.

EXAMINER


McNamee

DATE CONSIDERED

9/16/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Minotti et al.	CONFIRMATION NO.
		FILING DATE December 4, 2003	GROUP 1623



M

		Wahl et al. "Selective tumor sensitization to taxanes with the mab-drug conjugate CBR96-doxorubicin." Abstract: Int. J. Cancer vol. 4 (15 Aug. 2001), pages 590-600.
--	--	--

EXAMINER ANNALE DATE CONSIDERED 9/16/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.